New FLEXYTE® Protease Assays Enable Information-rich Output, Miniaturization and Multiplexing
April 7, 2010
Almac launches FLEXYTE® protease assay platform – the next step in exploration of fluorescent lifetime technology – at the 2010 Society for Biomolecular Sciences (SBS) meeting in Phoenix (11-15 April).
The new FLEXYTE® protease assays follow on from the great success of FLEXYTE® protein kinase assays launched in 2009. FLEXYTE® protease assays harness the power and potential of fluorescence lifetime technology for robust, efficient and economical screening of proteases. Avoiding radioactivity, antibodies and associated costs, fluorescence lifetime technology enables homogenous, robust and reliable assays with minimized interference from problem compounds, and will allow miniaturization, and multiplexing, while maintaining an information-rich output.
FLEXYTE® protease assays are based on labeled peptide substrates which have been developed for a variety of proteases. The generic peptide approach enables FLEXYTE® protease assays to be configured for a broad range of proteases. Almac will provide a custom assay development service for any protease of interest to customers.
Commenting on the launch of FLEXYTE® protease assays, Almac Sciences’ President and Managing Director, Stephen Barr said: “FLEXYTE® protease assays represent the next step in utilization of fluorescent lifetime technology to produce more robust, reliable and efficient assays in therapeutically important target classes.”
Almac will be exhibiting at the SBS meeting and will be available to provide more information on FLEXYTE® protease and protein kinase assays at booth 229.
Director Research Alliances
Almac Group Ltd.
T: +44 (0) 28 3839 5794
De Facto Communications
330 High Holborn
London WC1V 7QD
T: +44 (0)207 861 3838
Notes for Editors:
• FLEXYTE® dedicated technical presentations and supporting data are available on request to info@FLEXYTE-assays.com.
• To find out more about FLEXYTE®, visit www.flexyte-assays.com
FLEXYTE® harnesses the power and potential of fluorescence lifetime technology for robust, efficient and economical screening of protease kinases and proteases.
Avoiding radioactivity, antibodies and associated costs, fluorescence lifetime technology enables homogenous, robust and reliable assays with minimized interference from problem compounds, and will allow miniaturization, and multiplexing, while maintaining an information-rich output.
Generic substrates enable fluorescent lifetime assays to be configured for a broad panel of Ser/Thr protein kinases in a rapid fashion, covering over 100 different kinases – and with performance comparable to radiometric assays. The FLEXYTE® approach is applicable to any protein kinase having the appropriate peptide substrates. Assay reagents and protocols will be available in bulk form for high throughput screening or in kit form for lower capacity assays.
About Almac Group:
Almac is a financially stable, privately owned organization with over 30 years experience, it provides integrated development solutions to over 600 customers worldwide including all the world leaders in the pharmaceutical and biotechnology sectors. Their services include R&D, translational genomic services; API manufacture; formulation development; clinical trial supply and technology (IVRS/IWRS/ePRO) and commercial-scale manufacture.
The company has over 2,600 employees and is headquartered in Craigavon, Northern Ireland, where it was awarded “Business of the Year 2009”. US operations are based in Pennsylvania, North Carolina and California. Construction of the company’s new $120m North American Headquarters in PA started in July 2008 and will be completed in 2010.